Bhaumik Shah MD

Rates and Characteristics of Paid Malpractice Claims Among US Physicians by Specialty, 1992-2014. From 1992-1996 to 2009-2014, the rate of paid claims decreased by 55.7% (from 20.1 to 8.9 per 1000 physician-years) Diagnostic error was the most common type of allegation, present in 31.8% (35 349 of 111 066) of paid claims, ranging from 3.5% in anesthesiology (153 of 4317) to 87.0% in pathology (915 of 1052).... Mean increase $138 708 in pathology (from $335 249 in 1992-1996 to $473 957 in 2009-2014; P = .005). The mean compensation payment was $329 565. The mean payment increased by 23.3%, from $286 751 in 1992-1996 to $353 473 in 2009-2014. Of 280 368 paid claims, 21 271 (7.6%) exceeded $1 million (4304 of 69 617 [6.2%] in 1992-1996 and 4322 of 54 081 [8.0%] in 2009-2014), and 32.1% (35 293 of 109 865) involved a patient death. Decreases in Claims: Cardiology: - a 13.5% (from 15.6 to 13.5 per 1000 physician-years) Pediatrics - 75.8% (from 9.9 to 2.4 per 1000 physician-years). Increases: General Practice - $17 431 (from $218 350 in 1992-1996 to $235 781 in 2009-2014) Gastroenterology - $114 410 (from $276 128 in 1992-1996 to $390 538 in 2009-2014) and https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470361/

One investigational treatment being explored for COVID-19 involves the use of convalescent plasma collected from the recovered COVID-19 patients that are eligible to donate blood. 1. Prior diagnosis of COVID-19 documented by a laboratory test 2. Complete resolution of symptoms at least 14 days prior to donation 3. Female donors negative for HLA antibodies or male donors... 4. Negative results for COVID-19 either from one or more nasopharyngeal swab specimens or by a molecular diagnostic test from blood. Eligible patients for use under expanded access provisions: 1. Must have laboratory confirmed COVID-19 2. Must have severe or immediately life-threatening COVID-19, for example: 3. Severe disease is defined as: - dyspnea, - respiratory frequency 30/min, - blood oxygen saturation 93%, - partial pressure of arterial oxygen to fraction of inspired -oxygen ratio < 300, and/or - lung infiltrates > 50% within 24 to 48 hours Life-threatening disease is defined as: respiratory failure, septic shock, and/or multiple organ dysfunction or failure Must provide informed consent1. It is possible that convalescent plasma that contains antibodies to SARS-CoV-2 (the virus that causes COVID-19) might be effective against the infection. Use of convalescent plasma has been studied in outbreaks of other respiratory infections, including the 2009-2010 H1N1 influenza virus pandemic, 2003 SARS-CoV-1 epidemic, and the 2012 MERS-CoV epidemic. Although promising, convalescent plasma has not been shown to be effective in every disease studied. It is therefore important to determine through clinical trials, before routinely administering convalescent plasma to patients with COVID-19, that it is safe and effective to do so. https://www.fda.gov//investigational-covid-19-convalescent